ABSTRACT
Background: Gonadotropin-releasing hormone agonists [GnRH-a] was increasingly used for triggering oocyte maturationfor the prevention of ovarian hyperstimulation syndrome. Studies suggest that GnRH-a might be used as a better trigger agent since it causes both Luteinizing hormone and follicle stimulating hormone release from a physiologic natural cycle
Objective: The aim of this study was to evaluate the effect of dual-triggering in assisted reproductive technology outcomes
Materials and Methods: 192 normal responder women aged =42 years and 18< Body Mass Index <30 kg/m[2] enrolled in this single-blind randomized controlled trial. All participants received antagonist protocol. For final triggering, women randomly were divided into two groups. Group, I was triggered by 6500 IU human chorionic gonadotropin [hCG] alone, and group II by 6500 IU hCG plus 0.2 mg of triptorelin. The implantation, chemical, clinical and ongoing pregnancy, and abortion rates were measured
Results: The mean of retrieved oocytes and obtained embryos were statistically higher in the dual-trigger group [group I], but the implantation and pregnancy rates were similar in two groups
Conclusion: The results of our study did not confirm the favorable effect of dual-triggered oocyte maturation with a GnRH-a and a standard dosage of hCG as an effective strategy to optimize pregnancy outcome for normal responders in GnRH-antagonist cycles. We think that this new concept requires more studies before becoming a universal controlled ovarian hyperstimulation protocol in vitro fertilization practice